Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
pD2MXE080A1JhUuJ
